A*STAR Genome Institute of Singapore (A*STAR GIS)

Nuevocor, an A*STAR spin-off company, is designing novel therapies to target the genetic causes of heart diseases, bringing basic research to clinical impact.

Supported by A*STAR in the early days of their budding careers, scholars recount the experiences that opened the doors to bigger successes from academia to public service.

SARS-CoV-2 genome structures and their interactions with human RNA are shown to be important in virus survival and pathogenicity.

Honored with the President’s Science and Technology Awards, A*STAR researchers are shaping Singapore’s scientific landscape. Here, we spotlight three researchers who have pushed the boundaries in foundational biomedical research, translational engineering efforts and cross-cutting collaborations.

Through the years, A*STAR has always stood at the forefront of science and technology and innovation. Here’s how A*STAR came to be and what it has in store in the upcoming decades.

A new computational method called xPore identifies and estimates the number of specific RNA modifications in biological samples.

Using whole-exome sequencing, scientists have identified a gene likely linked to a common eye disorder that can lead to blindness in the elderly.

Using single-cell sequencing technology, A*STAR scientists have identified a rare population of liver cells susceptible to damage from SARS-CoV-2 infections.

Induced pluripotent stem cells have helped researchers map the role of the RFX6 gene in a rare congenital disorder known as Mitchell-Riley Syndrome.

Asian patients with suspected but undiagnosed rare genetic diseases could get answers sooner thanks to next-generation sequencing technologies.

Live bacterial strains present in fetal tissues may help lay the cornerstones of early and potentially life-long immunity.

Precise and efficient C:G to G:C gene-editing enzymes could pave the way for new treatments for genetic diseases.